PHILADELPHIA, Aug. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that it is scheduled to present at the upcoming Thomas Weisel Partners Healthcare Conference 2008 in Boston, Mass., on Thursday, September 4, 2008. Gearoid Faherty, Chief Executive Officer of Eurand, will be presenting.
Event: Thomas Weisel Partners Healthcare Conference 2008 Date: Thursday, September 4, 2008 Time: 10:20 a.m. ET Place: The Four Seasons Hotel
An audio webcast of the Company's presentation will be available by accessing the investor relations section of Eurand's web site at www.eurand.com. A replay of the presentation will be available until October 4, 2008.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four partnered products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand completed two Phase III clinical trials for EUR-1008 (Zentase(r)), intended for the treatment of Exocrine Pancreatic Insufficiency and, as announced on June 18, 2008, received an approvable letter from the FDA for its NDA for this product. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-masking/fast-dissolving orally disintegrating (ODT) formulations and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at www.eurand.com.